Literature DB >> 21788088

Structural and functional uncoupling of liver performance in the Fontan circulation.

Indra Neil Guha1, Sumit Bokhandi, Zaheer Ahmad, Nick Sheron, Richard Cope, Caroline Marshall, Gruschen Veldtman.   

Abstract

BACKGROUND: The liver is known to be structurally abnormal in long-standing Fontan circulation. The degree of liver dysfunction associated with such abnormalities is however largely unknown. We assessed structural changes (serum fibrosis markers) and function (indocyanine green clearance (ICG)) in Fontan patients.
METHODS: 21 stable Fontan patients were prospectively assessed and compared with 8 histologically proven compensated viral cirrhotic patients. All subjects had standard liver profile, "Enhanced Liver Fibrosis" (ELF) score (including hyaluronic acid, aminoterminal type III procollagen peptide P3NP and tissue inhibitor of metalloproteinase TIMP-1 levels), and ICG using the LiMON Device. Plasma disappearance rate (PDR) and 15-minute retention (R15) were recorded after ICG infusion.
RESULTS: Indocyanine clearance and retention (PDR and R15) were similar between Fontan and compensated cirrhotic patients (17 ± 5 vs 18 ± 6 (p=0.75) and 11 ± 10 vs 10 ± 10 (p=0.75)), as was degree of fibrosis (7.97 ± 1.16 vs 9.0 ± 1.43, p=NS). There was a positive correlation between PDR and ELF (R=0.77, p=0.028) as well as R15 and ELF (R=0.905, p=0.002) in the viral cirrhotics but not in the Fontan group. (R=-0.243, p=0.302; and R=0.226, p=0.338). PDR (17 ± 5) and R15 (11 ± 10) were not significantly different in Fontan as compared with the established cirrhotics.
CONCLUSIONS: Fontan patients have similar global hepatic function and fibrosis as compared with viral cirrhotic patients. However in Fontan patients, fibrosis was not closely correlated with global liver function, whereas viral cirrhotic patients exhibited a close correlation between function and fibrosis.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21788088     DOI: 10.1016/j.ijcard.2011.06.062

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  12 in total

1.  Percutaneous liver biopsy in Fontan patients.

Authors:  Abhay Srinivasan; Anthony K Guzman; Elizabeth B Rand; Jack Rychik; David J Goldberg; Pierre A Russo; Anne Marie Cahill
Journal:  Pediatr Radiol       Date:  2018-11-30

2.  Liver Strain Using Feature Tracking of Cine Cardiac Magnetic Resonance Imaging: Assessment of Liver Dysfunction in Patients with Fontan Circulation and Tetralogy of Fallot.

Authors:  Ryoko Ohashi; Michinobu Nagao; Umiko Ishizaki; Yumi Shiina; Kei Inai; Shuji Sakai
Journal:  Pediatr Cardiol       Date:  2019-12-18       Impact factor: 1.655

Review 3.  MR assessment of abdominal circulation in Fontan physiology.

Authors:  Shi-Joon Yoo; Milan Prsa; Daryl Schantz; Lars Grosse-Wortmann; Mike Seed; Tae Kyoung Kim; Rachel Wald; Rajiv Chaturvedi
Journal:  Int J Cardiovasc Imaging       Date:  2014-04-22       Impact factor: 2.357

4.  The impact of liver disorders on perioperative management of reoperative cardiac surgery: a retrospective study in adult congenital heart disease patients.

Authors:  Koko Adachi; Hiroaki Toyama; Yu Kaiho; Osamu Adachi; Hiroto Hudeta; Masanori Yamauchi
Journal:  J Anesth       Date:  2017-01-16       Impact factor: 2.078

5.  Fontan Outcomes and Pulmonary Blood Flow at Birth.

Authors:  William N Evans; Ruben J Acherman; Leigh C Reardon; Michael L Ciccolo; Alvaro Galindo; Abraham Rothman; Brody J Winn; Noel S Yumiaco; Humberto Restrepo
Journal:  Pediatr Cardiol       Date:  2015-07-18       Impact factor: 1.655

6.  Liver cirrhosis in Fontan patients does not affect 1-year post-heart transplant mortality or markers of liver function.

Authors:  Kathleen E Simpson; Amir Esmaeeli; Geetika Khanna; Francis White; Yumirle Turnmelle; Pirooz Eghtesady; Umar Boston; Charles E Canter
Journal:  J Heart Lung Transplant       Date:  2013-10-25       Impact factor: 10.247

7.  Fontan Liver Disease: Review of an Emerging Epidemic and Management Options.

Authors:  Elisa Bradley; Benjamin Hendrickson; Curt Daniels
Journal:  Curr Treat Options Cardiovasc Med       Date:  2015-11

8.  Altered Cholesterol Metabolism and Hypocholesterolemia in Patients with Single Ventricle following Fontan Palliation.

Authors:  Wendy Whiteside; Meng Tan; Richard E Ostlund; Sunkyung Yu; Lina Ma; Albert Rocchini
Journal:  J Pediatr       Date:  2016-01-21       Impact factor: 4.406

Review 9.  Beyond a broken heart: circulatory dysfunction in the failing Fontan.

Authors:  Makoto Mori; Alfredo J Aguirre; Robert W Elder; Ali Kashkouli; Alton Brad Farris; Ryan M Ford; Wendy M Book
Journal:  Pediatr Cardiol       Date:  2014-02-15       Impact factor: 1.655

10.  Features of portal hypertension are associated with major adverse events in Fontan patients: the VAST study.

Authors:  Robert W Elder; Nancy M McCabe; Camden Hebson; Emir Veledar; Rene Romero; Ryan M Ford; William T Mahle; Brian E Kogon; Anurag Sahu; Maan Jokhadar; Michael E McConnell; Wendy M Book
Journal:  Int J Cardiol       Date:  2013-07-09       Impact factor: 4.164

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.